Actively Recruiting
Evaluating the Safety of Omitting Radiation Therapy After Lumpectomy in Low-risk HER2-positive Breast Cancer Patients Receiving HER2-targeted Therapy
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-10-29
136
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether it is safe to skip radiation therapy to the breast after lumpectomy in people with low-risk HER2-positive breast cancer who are receiving HER2-targeted therapy. This study focuses on patients who have received breast conserving surgery and systemic HER2-targeted treatment. The goal is to determine the rate of cancer recurrence in the same breast over a 5-year period without radiation therapy. Participants will continue standard HER2-targeted therapy as part of their usual care and may also receive endocrine therapy if their cancer is hormone receptor-positive. Radiation therapy to the breast will be omitted after lumpectomy. The study includes patients who have completed neoadjuvant or adjuvant systemic therapy within 90 days before enrollment and meet specific tumor size and nodal evaluation criteria. During the study, participants will be monitored for cancer recurrence in the treated breast over 5 years. Researchers will evaluate safety and recurrence rates without radiation, following tumor and nodal status according to established guidelines. Participants will have imaging such as mammograms or MRIs within 52 weeks prior to enrollment and will be regularly assessed as part of their ongoing care throughout the study period.
CONDITIONS
Brief Title
A Study of Skipping Radiation Therapy in People With Breast Cancer
Research Team
L
Lior Braunstein, MD
D
Diana Roth O'Brien, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here